Melanoma Program (Project-008)

翻译后摘要：黑色素瘤计划（MP） 黑色素瘤项目（MP）的总体使命是改善患有黑色素瘤的患者的临床结果。 黑素瘤MP成员进行基础和转化研究，以阐明 黑色素瘤的进展，以及黑色素瘤免疫逃逸的关键途径， 用于晚期和辅助性疾病的新疗法。国会议员福尔斯的研究结果低于三个 中心主题：1）黑色素瘤的免疫学和免疫治疗; 2）黑色素瘤的研究和治疗 脑转移;和3）新的化疗药物启动的试验（IIT）以及辅助和新的化疗药物的组合。 可切除疾病的辅助干预以及黑素瘤的早期检测和预防。 MP的具体目标是：1）了解进展的基本肿瘤和免疫机制， 对治疗的抗性; 2）鉴定在辅助治疗的患者中临床结果的新生物标志物， 新辅助治疗和晚期疾病环境;以及3）将实验室结果转化为新型IIT， 在UPCI和合作小组的相关研究。该方案有13名成员，代表6个 在匹兹堡大学的两所学校的部门。该计划得到了NIH/NCI校外赠款的支持 包括NCI黑色素瘤和皮肤癌卓越研究专业计划（SPORE）。MP 成员目前每年共获得420万美元的直接资助，其中几乎所有的同行评审支持 由NCI提供（180万美元）。在2010年1月至2014年4月期间，议员们发表了190份癌症报告， 相关出版物，其中38%来自计划内，46%来自计划间 合作。大约41%的论文代表与外部研究者的合作。 每周的翻译研究会议促进了合作努力，审查所有活跃和未决的 MP临床试验，以及每周临床病理学审查和每月研究研讨会， 来自多个其他UPCI计划的成员一起进行跨学科的科学讨论。II期 ECOG-ACRIN合作小组的第三和第四项研究部分来自MP的工作， 成员积极参与国家合作小组的研究议程，并担任领导 ECOG-ACRIN和组间倡议的研究者或共同研究者。UPCI支持，包括临床 方案和数据管理以及共享资源，特别是生物统计学设施，癌症 生物信息学服务，癌症基因组学机构，癌症药代动力学和药效学机构， 癌症蛋白质组学设施，细胞和组织成像设施，细胞计数设施，免疫监测和 细胞产品实验室、体内成像机构、研究药物服务和组织与研究 病理学服务促进和加强MP研究。

Abstract: Melanoma Program (MP) The overall mission of the Melanoma Program (MP) is to improve the clinical outcome of patients with melanoma. MP members conduct basic and translational research studies to elucidate the mechanisms of melanoma progression, and the critical pathways of melanoma immune escape, to translate laboratory findings into novel therapies for both advanced and adjuvant disease settings. Research within the MP falls under three central themes: 1) immunology and immunotherapy of melanoma; 2) investigation and treatment of melanoma brain metastasis; and 3) novel investigator-initiated trials (IITs) and combinations for adjuvant and neo- adjuvant interventions for resectable disease as well as for the early detection and prevention of melanoma. Specific aims of the MP are to: 1) understand the basic tumor and immune mechanisms of progression and resistance to therapy; 2) identify new biomarkers of clinical outcome in patients treated in the adjuvant, neoadjuvant, and advanced disease settings; and 3) translate laboratory findings into novel IITs with correlative studies at UPCI and in the cooperative groups. The Program has 13 members representing 6 departments in 2 schools at the University of Pittsburgh. The MP is supported by NIH/NCI extramural grants including an NCI Specialized Program of Research Excellence (SPORE) in Melanoma and Skin Cancer. MP members currently receive a total of $4.2 M in annual direct funding, of which nearly all peer-reviewed support is provided by the NCI ($1.8 M). Between January 2010 and April 2014, MP members published 190 cancer- related publications, of which 38% resulted from intra-programmatic and 46% from inter-programmatic collaborations. Approximately 41% of the papers represent collaborations with external investigators. Collaborative efforts are fostered by weekly translational research meetings that review all active and pending MP clinical trials, as well as weekly clinical pathology reviews and monthly research seminars that bring members from multiple other UPCI programs together for interdisciplinary scientific discussion. The phase II and III studies of the ECOG-ACRIN Cooperative Group have emerged in part from the work of the MP, whose members are actively engaged in the research agenda of the National Cooperative Groups, and serve as lead investigators or co-investigators on ECOG-ACRIN and Intergroup initiatives. UPCI support, including Clinical Protocol and Data Management and Shared Resources, specifically the Biostatistics Facility, Cancer Bioinformatics Services, Cancer Genomics Facility, Cancer Pharmacokinetics and Pharmacodynamics Facility, Cancer Proteomics Facility, Cell and Tissue Imaging Facility, Cytometry Facility, Immunological Monitoring and Cellular Products Laboratory, In Vivo Imaging Facility, Investigational Drug Services, and Tissue and Research Pathology Services facilitates and enhances MP research.